CRISPR Z Score

CRSP
 Stock
  

USD 77.46  1.41  1.79%   

Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Continue to CRISPR Therapeutics Piotroski F Score and CRISPR Therapeutics Valuation analysis.
  
CRISPR Therapeutics Return on Invested Capital is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Return on Invested Capital of 0.26. As of 11th of August 2022, Invested Capital is likely to grow to about 2.1 B, while Capital Expenditure is likely to drop (83.9 M). CRISPR Therapeutics Operating Income is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Operating Income of 373.53 Million. As of 11th of August 2022, Revenues is likely to grow to about 987.2 M, while Weighted Average Shares is likely to drop about 62.1 M.

CRISPR Z Score Analysis

CRISPR Therapeutics' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
 2021 2022 (projected)
Interest Expense9.26 M9.99 M
Gross Profit914.96 M987.2 M
Z Score 
 = 
Sum Of  
 
5 Factors 
More About Z Score | All Equity Analysis

Current CRISPR Therapeutics Z Score

    
  21.3  
Most of CRISPR Therapeutics' fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CRISPR Therapeutics AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
First Factor
 = 
1.2 * (
Working Capital
/
Total Assets )
Second Factor
 = 
1.4 * (
Retained Earnings
/
Total Assets )
Thrid Factor
 = 
3.3 * (
EBITAD
/
Total Assets )
Fouth Factor
 = 
0.6 * (
Market Value of Equity
/
Total Liabilities )
Fifth Factor
 = 
0.99 * (
Revenue
/
Total Assets )

CRISPR Z Score Driver Correlations

Understanding the fundamental principles of building solid financial models for CRISPR Therapeutics is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Z Score. Since CRISPR Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of CRISPR Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of CRISPR Therapeutics' interrelated accounts and indicators.
To calculate Z-Score one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. Z-Score can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area' with scores of less than 1, indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
Compare to competition

In accordance with the company's disclosures, CRISPR Therapeutics AG has a Z Score of 21.3. This is 215.56% higher than that of the Healthcare sector and notably higher than that of the Biotechnology industry. The z score for all United States stocks is 144.27% lower than that of the firm.

CRISPR Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of CRISPR Therapeutics from analyzing CRISPR Therapeutics' financial statements. These drivers represent accounts that assess CRISPR Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of CRISPR Therapeutics' important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Average Assets295.25 M433.88 M694.87 M1.34 B2.61 B2.81 B
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(63.58 M)(160.91 M)72.03 M(338.87 M)397.48 M428.86 M
Earnings Before Interest Taxes and Depreciation Amortization USD(63.58 M)(160.91 M)72.03 M(338.87 M)397.48 M428.86 M
Earnings before Tax(66.61 M)(164.43 M)67.31 M(348.06 M)379.53 M409.49 M
Average Equity194.94 M341.25 M569.7 M1.2 B2.33 B2.51 B
Enterprise Value706.46 M992.24 M2.77 B9.81 B4.98 B4.53 B
Free Cash Flow(77.91 M)(99.01 M)49.99 M(256.72 M)457.27 M493.37 M
Invested Capital13.58 M1.17 M113.14 M609.49 M1.92 B2.07 B
Invested Capital Average13.29 M5.81 M74.92 M295.1 M1.48 B1.6 B
Market Capitalization963.13 M1.48 B3.36 B10.82 B5.8 B5.29 B
Tangible Asset Value271 M488.73 M1.07 B1.83 B2.75 B2.97 B
Working Capital233.87 M438.65 M930.44 M1.62 B2.3 B2.48 B

CRISPR Therapeutics Institutional Holders

Institutional Holdings refers to the ownership stake in CRISPR Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of CRISPR Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing CRISPR Therapeutics' value.
Security TypeSharesValue
Ark Investment Management LlcCommon Shares9.7 M564.7 M
Sumitomo Mitsui Trust Holdings IncCommon Shares4.6 M278.6 M
Nikko Asset Management Americas IncCommon Shares4.6 M276.1 M
Loomis Sayles Co L PCommon Shares1.4 M84.8 M
Pictet Asset Management SaCommon Shares423.3 K25.7 M
Allspring Global Investments Holdings LlcCommon Shares273.8 K16.6 M
Lazard Asset Management LlcCommon Shares264.1 K16.1 M
Imcchicago LlcCall Options209.5 K12.7 M
Walleye Trading LlcPut Options164.6 K10 M

CRISPR Fundamentals

About CRISPR Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze CRISPR Therapeutics AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CRISPR Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CRISPR Therapeutics AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-associated protein 9 platform. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. CRISPR Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 473 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in CRISPR Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Stock Screener Now

   

Stock Screener

Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
All  Next Launch Module

Pair Trading with CRISPR Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CRISPR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CRISPR Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with CRISPR Therapeutics

0.88ADGIAdagio Therapeutics Earnings Call  TomorrowPairCorr

Moving against CRISPR Therapeutics

0.91BBIBrickell Biotech Earnings Call  TodayPairCorr
0.85AGRXAgile Therapeutics Earnings Call  TodayPairCorr
0.78ABCAmerisourcebergen Corp Fiscal Year End 3rd of November 2022 PairCorr
0.71ACBAurora Cannabis Fiscal Year End 26th of September 2022 PairCorr
The ability to find closely correlated positions to CRISPR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CRISPR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CRISPR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CRISPR Therapeutics AG to buy it.
The correlation of CRISPR Therapeutics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CRISPR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CRISPR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CRISPR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to CRISPR Therapeutics Piotroski F Score and CRISPR Therapeutics Valuation analysis. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
6.2 B
Quarterly Revenue Growth YOY
-1.0
Return On Assets
-0.15
Return On Equity
-0.27
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.